Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Arends J; Willms BH
  • Source:
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme [Horm Metab Res] 1986 Nov; Vol. 18 (11), pp. 761-4.
  • Publication Type:
    Clinical Trial; Controlled Clinical Trial; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Thieme Country of Publication: Germany NLM ID: 0177722 Publication Model: Print Cited Medium: Print ISSN: 0018-5043 (Print) Linking ISSN: 00185043 NLM ISO Abbreviation: Horm Metab Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: Stuttgart, Thieme.
    • Subject Terms:
      Glycoside Hydrolase Inhibitors*; Blood Glucose/*metabolism ; Diabetes Mellitus, Type 2/*drug therapy ; Sulfonylurea Compounds/*therapeutic use; 1-Deoxynojirimycin/analogs & derivatives ; Adult ; Circadian Rhythm ; Diabetes Mellitus, Type 2/blood ; Drug Therapy, Combination ; Female ; Glucosamine/analogs & derivatives ; Glucosamine/therapeutic use ; Humans ; Imino Pyranoses ; Male ; Middle Aged
    • Abstract:
      The alpha-glucosidase inhibitor BAY m 1099, a deoxynojirimycin derivative, was studied in sulfonylurea-treated type II diabetic patients using a placebo-controlled double-blind cross-over design. Given in two daily doses the inhibitor smoothened the blood glucose profile by lowering significantly post-prandial blood glucose peaks. Fasting and daily mean blood glucose levels measured as the area under the blood glucose curves were however not influenced significantly. This might be due to the short duration of the treatment periods or the low dosage of the drug. Abdominal side effects were negligible. The alpha-glucosidase inhibitor BAY m 1099 might become a useful therapeutic tool in addition to sulfonylurea treatment in type II diabetes.
    • Accession Number:
      0 (Blood Glucose)
      0 (Glycoside Hydrolase Inhibitors)
      0 (Imino Pyranoses)
      0 (Sulfonylurea Compounds)
      0V5436JAQW (miglitol)
      19130-96-2 (1-Deoxynojirimycin)
      N08U5BOQ1K (Glucosamine)
    • Publication Date:
      Date Created: 19861101 Date Completed: 19870218 Latest Revision: 20141120
    • Publication Date:
      20221208
    • Accession Number:
      10.1055/s-2007-1012429
    • Accession Number:
      3539737